View Future GrowthAbClon 과거 순이익 실적과거 기준 점검 0/6AbClon 의 수입은 연평균 -16.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.2%의 비율로 증가했습니다. 매출은 연평균 3.6%의 비율로 증가해 왔습니다.핵심 정보-16.77%순이익 성장률-14.42%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률3.58%자기자본이익률-25.24%순이익률-317.07%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updates공고 • Mar 04AbClon Inc., Annual General Meeting, Mar 23, 2026AbClon Inc., Annual General Meeting, Mar 23, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 30, eunhaeng-ro, yeongdeungpo-gu, seoul South KoreaNew Risk • Nov 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.6m).Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).공고 • Oct 03AbClon Inc. announced that it expects to receive KRW 10.799952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture CapitalAbClon Inc. announced private placement of 592,655 convertible preferred shares at a price of KRW 18,223 for gross proceeds of KRW 10,799,952,065 on October 1, 2025. The transaction includes participation from DSC Home Run Fund No. 2 for 214,015 shares, DSC Dominance Fund I for 32,925 shares, Paratus Innovation Growth M&A No. 2 for 246,940 shares, Dongyu Investment Co Ltd. for 49,388 shares, Alpha View Partners Co., Ltd. for 32,925 shares, Winvest Venture Capital for 16,462 shares. The preferred shares are 100% convertible into 592,655 shares at a conversion price of KRW 18,223 from conversion period of November 7, 2026 to October 28, 2030. The preferred dividend rate for the company’s preferred stock is 1.0% per annum. The shares have a restriction period of 1 year. The transaction is expected to close on October 28, 2025. The transaction is approved by board of directors of the company.New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).분석 기사 • Sep 08Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Aug 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).공고 • May 20AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.On May 19, 2025, AbClon Inc. closed the transaction.New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩2.3b revenue, or US$1.7m).공고 • May 09AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.AbClon Inc. announced a private placement to issue 1,400,000 shares at an issue price of KRW 8723 for gross proceeds of KRW 12,212,200,000 on May 9, 2025. The transaction includes participation from Chong Kun Dang Pharmaceutical Corp. for 1,400,000 shares.New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.4b revenue, or US$1.6m). Market cap is less than US$100m (₩141.6b market cap, or US$96.9m).공고 • Mar 07AbClon Inc., Annual General Meeting, Mar 31, 2025AbClon Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea공고 • Oct 29AbClon Inc. announced that it expects to receive KRW 30.999884504 billion in funding from The Korea Securities Finance Corporation, Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Shinhan Bank, GC Tech Company Limited and another investorAbClon Inc announced a private placement to issue convertible bonds for gross proceeds KRW 20,000,000,000 and 677,166 common shares at price KRW16,244 for gross proceeds KRW 10,999,884,504, for aggregate gross proceeds KRW 30,999,884,504 on October 28, 2024. The notes bear zero interest and matures on November 29, 2029 for Conversion Period starts from November 29, 2025 to October 29, 2029. The transaction is expected to close on November 29, 2024. The transaction includes participation from Mirae Asset Securities Co., Ltd, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd, The Korea Securities Finance Corporation, Shinhan Bank, GC Tech Company Limited and Dayli Bio Healthcare No.6 Start-Up Venture Private Equity Fund Co., Ltd. The transaction was approved by board of directors. The transaction is expected to close on November 29, 2024.분석 기사 • Aug 04Here's Why AbClon (KOSDAQ:174900) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • May 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Revenue is less than US$5m (₩2.6b revenue, or US$1.9m).분석 기사 • Apr 23Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.5b revenue, or US$2.7m).공고 • Sep 30AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.On September 28, 2022, AbClon Inc. closed the transaction.공고 • Jul 28+ 2 more updatesAbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.On July 28, 2022, AbClon Inc. closed the transaction.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.공고 • Feb 25AbClon Inc., Annual General Meeting, Mar 29, 2021AbClon Inc., Annual General Meeting, Mar 29, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Feb 24New 90-day low: ₩27,600The company is down 5.0% from its price of ₩28,950 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.분석 기사 • Feb 16Does AbClon (KOSDAQ:174900) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Dec 25The AbClon (KOSDAQ:174900) Share Price Is Up 85% And Shareholders Are Holding OnIf you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...Is New 90 Day High Low • Dec 21New 90-day high: ₩37,250The company is up 3.0% from its price of ₩36,000 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 11New 90-day low: ₩27,350The company is down 26% from its price of ₩36,750 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: ₩30,650The company is down 14% from its price of ₩35,450 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩31,800The company is down 20% from its price of ₩39,800 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.매출 및 비용 세부 내역AbClon가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A174900 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 264,736-15,0153,84712,05931 Dec 254,714-18,1044,02514,43130 Sep 253,801-16,2303,58012,53830 Jun 253,033-16,1343,36212,91631 Mar 252,315-16,6293,20613,06831 Dec 242,340-16,3022,67313,39430 Sep 242,193-18,1732,67814,02630 Jun 242,072-18,9762,63614,71131 Mar 242,437-16,5252,53013,72331 Dec 232,877-12,9042,45410,73430 Sep 233,005-9,4241,9579,32430 Jun 233,267-7,7822,2737,58831 Mar 233,468-8,7282,1028,28031 Dec 223,404-9,2442,0238,69330 Sep 223,170-9,7592,4868,80630 Jun 222,912-8,9641,9468,34231 Mar 223,262-11,0271,91110,33331 Dec 213,018-10,2381,8319,62630 Sep 213,232-9,9051,7069,23630 Jun 213,260-9,1781,6698,59931 Mar 212,482-6,7311,6175,69131 Dec 202,771-6,4451,5575,85930 Sep 203,196-5,5381,4165,56530 Jun 203,005-5,1321,5955,09331 Mar 203,258-4,5341,8013,87931 Dec 1914,3752,5675,0682,81630 Sep 1914,7584,0395,3392,50730 Jun 1914,8833,8985,1632,71431 Mar 1914,7534,8024,9262,65531 Dec 183,921-8431,6052,36830 Sep 183,031-2,0471,4712,02230 Jun 182,908-1,8501,4581,78931 Mar 183,094-1,5781,4551,70731 Dec 173,532-1,4831,7151,71730 Sep 173,421-1,6441,6321,83130 Jun 173,497-1,6171,5971,86031 Mar 174,193-9511,5421,98231 Dec 163,120-1,5971,2751,99230 Sep 163,173-1,9492483,32930 Jun 163,047-1,7948192,87931 Mar 161,994-2,7671,3432,29031 Dec 151,948-9,8421,6071,852양질의 수익: A174900 은(는) 현재 수익성이 없습니다.이익 마진 증가: A174900는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A174900은 수익성이 없으며 지난 5년 동안 손실이 연평균 16.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A174900의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A174900은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A174900는 현재 수익성이 없으므로 자본 수익률이 음수(-25.24%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/05 23:12종가2026/08/05 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AbClon Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Wan KuNH Investment & Securities Co., Ltd.Eun Saem LeeShinhan Investment Corp.
Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
공고 • Mar 04AbClon Inc., Annual General Meeting, Mar 23, 2026AbClon Inc., Annual General Meeting, Mar 23, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 30, eunhaeng-ro, yeongdeungpo-gu, seoul South Korea
New Risk • Nov 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.6m).
Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).
공고 • Oct 03AbClon Inc. announced that it expects to receive KRW 10.799952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture CapitalAbClon Inc. announced private placement of 592,655 convertible preferred shares at a price of KRW 18,223 for gross proceeds of KRW 10,799,952,065 on October 1, 2025. The transaction includes participation from DSC Home Run Fund No. 2 for 214,015 shares, DSC Dominance Fund I for 32,925 shares, Paratus Innovation Growth M&A No. 2 for 246,940 shares, Dongyu Investment Co Ltd. for 49,388 shares, Alpha View Partners Co., Ltd. for 32,925 shares, Winvest Venture Capital for 16,462 shares. The preferred shares are 100% convertible into 592,655 shares at a conversion price of KRW 18,223 from conversion period of November 7, 2026 to October 28, 2030. The preferred dividend rate for the company’s preferred stock is 1.0% per annum. The shares have a restriction period of 1 year. The transaction is expected to close on October 28, 2025. The transaction is approved by board of directors of the company.
New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
분석 기사 • Sep 08Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Aug 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
공고 • May 20AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.On May 19, 2025, AbClon Inc. closed the transaction.
New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩2.3b revenue, or US$1.7m).
공고 • May 09AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.AbClon Inc. announced a private placement to issue 1,400,000 shares at an issue price of KRW 8723 for gross proceeds of KRW 12,212,200,000 on May 9, 2025. The transaction includes participation from Chong Kun Dang Pharmaceutical Corp. for 1,400,000 shares.
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.4b revenue, or US$1.6m). Market cap is less than US$100m (₩141.6b market cap, or US$96.9m).
공고 • Mar 07AbClon Inc., Annual General Meeting, Mar 31, 2025AbClon Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea
공고 • Oct 29AbClon Inc. announced that it expects to receive KRW 30.999884504 billion in funding from The Korea Securities Finance Corporation, Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Shinhan Bank, GC Tech Company Limited and another investorAbClon Inc announced a private placement to issue convertible bonds for gross proceeds KRW 20,000,000,000 and 677,166 common shares at price KRW16,244 for gross proceeds KRW 10,999,884,504, for aggregate gross proceeds KRW 30,999,884,504 on October 28, 2024. The notes bear zero interest and matures on November 29, 2029 for Conversion Period starts from November 29, 2025 to October 29, 2029. The transaction is expected to close on November 29, 2024. The transaction includes participation from Mirae Asset Securities Co., Ltd, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd, The Korea Securities Finance Corporation, Shinhan Bank, GC Tech Company Limited and Dayli Bio Healthcare No.6 Start-Up Venture Private Equity Fund Co., Ltd. The transaction was approved by board of directors. The transaction is expected to close on November 29, 2024.
분석 기사 • Aug 04Here's Why AbClon (KOSDAQ:174900) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • May 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Revenue is less than US$5m (₩2.6b revenue, or US$1.9m).
분석 기사 • Apr 23Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.5b revenue, or US$2.7m).
공고 • Sep 30AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.On September 28, 2022, AbClon Inc. closed the transaction.
공고 • Jul 28+ 2 more updatesAbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.On July 28, 2022, AbClon Inc. closed the transaction.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
공고 • Feb 25AbClon Inc., Annual General Meeting, Mar 29, 2021AbClon Inc., Annual General Meeting, Mar 29, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Feb 24New 90-day low: ₩27,600The company is down 5.0% from its price of ₩28,950 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.
분석 기사 • Feb 16Does AbClon (KOSDAQ:174900) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Dec 25The AbClon (KOSDAQ:174900) Share Price Is Up 85% And Shareholders Are Holding OnIf you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...
Is New 90 Day High Low • Dec 21New 90-day high: ₩37,250The company is up 3.0% from its price of ₩36,000 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 11New 90-day low: ₩27,350The company is down 26% from its price of ₩36,750 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: ₩30,650The company is down 14% from its price of ₩35,450 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩31,800The company is down 20% from its price of ₩39,800 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.